Enzyme inhibition by metal complexes: concepts, strategies and applications

被引：207

作者：

Kilpin, Kelly J. ^{[1
]}

Dyson, Paul J. ^{[1
]}

机构：

[1] Ecole Polytech Fed Lausanne, Inst Sci & Ingn Chim, CH-1015 Lausanne, Switzerland

来源：

CHEMICAL SCIENCE | 2013年 / 4卷 / 04期

关键词：

HALF-SANDWICH COMPLEXES; PROTEIN-KINASE INHIBITORS; RATIONAL DESIGN; ANTITUMOR DRUGS; ANTICANCER COMPLEXES; CYSTEINE PROTEASES; GOLD(I) COMPOUNDS; TRANSFERASE P1-1; CHEMICAL SPACE; CATHEPSIN-B;

D O I：

10.1039/c3sc22349c

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Metal complexes are increasingly being used to inhibit enzymes. The reasons for this increased interest arise from the special features that metal complexes offer, e.g. the facile construction of 3D architectures that tightly fill enzyme active sites increasing selectivity and the possibility of facile coordination to protein residues that enhances enzyme inhibition. In this review we classify the main modes of enzyme inhibition by metal-based complexes and correlate the enzyme inhibition activity to macroscopic properties such as anticancer activity.

引用

页码：1410 / 1419

页数：10

共 96 条

[1] Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs [J].

Ang, Wee Han ;

De Luca, Anastasia ;

Chapuis-Bernasconi, Catherine ;

Juillerat-Jeanneret, Lucienne ;

Lo Bello, Mario ;

Dyson, Paul J. .

CHEMMEDCHEM, 2007, 2 (12) :1799-1806

[2] Classical and non-classical ruthenium-based anticancer drugs: Towards targeted chemotherapy [J].

Ang, Wee Han ;

Dyson, Paul J. .

EUROPEAN JOURNAL OF INORGANIC CHEMISTRY, 2006, (20) :4003-4018

[3] Rational Design of an Organometallic Glutathione Transferase Inhibitor [J].

Ang, Wee Han ;

Parker, Lorien J. ;

De Luca, Anastasia ;

Juillerat-Jeanneret, Lucienne ;

Morton, Craig J. ;

Lo Bello, Mario ;

Parker, Michael W. ;

Dyson, Paul J. .

ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2009, 48 (21) :3854-3857

[4] Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance [J].

Ang, WH ;

Khalaila, I ;

Allardyce, CS ;

Juillerat-Jeanneret, L ;

Dyson, PJ .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2005, 127 (05) :1382-1383

[5] Structure of anticancer ruthenium half-sandwich complex bound to glycogen synthase kinase 3β [J].

Atilla-Gokcumen, G. Ekin ;

Di Costanzo, Luigi ;

Meggers, Eric .

JOURNAL OF BIOLOGICAL INORGANIC CHEMISTRY, 2011, 16 (01) :45-50

[6] Extremely Tight Binding of a Ruthenium Complex to Glycogen Synthase Kinase 3 [J].

Atilla-Gokcumen, G. Ekin ;

Pagano, Nicholas ;

Streu, Craig ;

Maksimoska, Jasna ;

Filippakopoulos, Panagis ;

Knapp, Stefan ;

Meggers, Eric .

CHEMBIOCHEM, 2008, 9 (18) :2933-2936

[7] '3+1' mixed-ligand oxorhenium(V) complexes and their inhibition of the cysteine proteases cathepsin B and cathepsin K [J].

Baird, Ian R. ;

Mosi, Renee ;

Olsen, Micki ;

Cameron, Beth R. ;

Fricker, Simon P. ;

Skerlj, Renato T. .

INORGANICA CHIMICA ACTA, 2006, 359 (09) :2736-2750

[8] Approaching tumour therapy beyond platinum drugs Status of the art and perspectives of ruthenium drug candidates [J].

Bergamo, A. ;

Gaiddon, C. ;

Schellens, J. H. M. ;

Beijnen, J. H. ;

Sava, G. .

JOURNAL OF INORGANIC BIOCHEMISTRY, 2012, 106 (01) :90-99

[9] Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs [J].

Bergamo, Alberta ;

Sava, Gianni .

DALTON TRANSACTIONS, 2011, 40 (31) :7817-7823

[10] Gold compounds as therapeutic agents for human diseases [J].

Berners-Price, Susan J. ;

Filipovska, Aleksandra .

METALLOMICS, 2011, 3 (09) :863-873

← 1 2 3 4 5 6 7 8 9 10 →